A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-027)
Status:
Completed
Trial end date:
2020-08-17
Target enrollment:
Participant gender:
Summary
The main objectives of this study will be to evaluate the efficacy of gefapixant in reducing
cough frequency as measured over a 24-hour period at Week 12, and to evaluate the safety and
tolerability of gefapixant. The primary hypothesis is that at least one gefapixant dose is
superior to placebo in reducing coughs per hour (over 24 hours) at Week 12.